Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)

Documenti analoghi

• Risk of acute pancreatitis with DPP ‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation
  di: Takashi Tatewaki, et al.
  Pubblicazione: (2026)
• Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy
  di: Frank M. Gao, et al.
  Pubblicazione: (2025)
• Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
  di: Myung Jin Kim, et al.
  Pubblicazione: (2025)
• Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
  di: Kiichi Hirayama, et al.
  Pubblicazione: (2025)
• Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
  di: Gregor A. Maier, et al.
  Pubblicazione: (2026)